Raphael Olivier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raphael Olivier has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- David Tougeron
CHU de Poitiers, Poitiers, France
2 shared publications Jérémie Jacques
2 shared publicationsAbdelkader Taibi
Limoges University Hospital Center, Hepato-Gastroenterology Department, Limoges, France
1 shared publication- Anne Hay-Lombardie
Department of Biochemistry, University Hospital of Nantes, 44093 Nantes, France
1 shared publication - Damien Masson
Faculty of Medicine, University of Nantes, 44300 Nantes, France
1 shared publication - Dominique Lamarque
Unit of Hepato-Gastroenterology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris CHU Paris IdF Ouest, Boulogne-Billancourt, France
1 shared publication
Latest Publications
- 1 November 2022
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 29 (9) , 1086-1090
Endoscopie et gastroparésie : où en est-on ?
- 1 November 2022
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 29 (9) , 1086-1090
Endoscopie et gastroparésie : où en est-on ?
- Open Access
- 12 March 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (3) , 695
Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study
Background: Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), a gastric precancerous lesion, is of growing interest for identification of patients at increased risk of gastric cancer. The aim was to analyze the diagnostic performance of serum pepsinogen testing using another method, chemiluminescent enzyme immunoassay (CLEIA), as well as of other new potential biomarkers. Material and Methods: The sera of patients considered at increased risk of gastric cancer and undergoing upper endoscopy collected in our previous prospective, multicenter study were tested for pepsinogen I (PGI) and II (PGII), interleukin-6 (IL-6), human epididymal protein 4 (HE-4), adiponectin, ferritin and Krebs von den Lungen (KL-6) using the CLEIA. The diagnostic performance for the detection of AG was calculated by taking histology as the reference. Results: In total, 356 patients (162 men (46%); mean age 58.6 (±14.2) years), including 152 with AG, were included. For the detection of moderate to severe corpus AG, sensitivity and specificity of the pepsinogen I/II ratio were of 75.0% (95%CI 57.8–87.9) and 92.6% (88.2–95.8), respectively. For the detection of moderate to severe antrum AG, sensitivity of IL-6 was of 72.2% (95%CI 46.5–90.3). Combination of pepsinogen I/II ratio or HE-4 showed a sensitivity of 85.2% (95%CI 72.9–93.4) for the detection of moderate to severe AG at any location. Conclusion: This study shows that PG testing by CLEIA represents an accurate assay for the detection of corpus AG. Additionally, IL-6 and HE-4 may be of interest for the detection of antrum AG. Mini- Pepsinogens testing by chemiluminescent enzyme immunoassay is accurate for the detection of corpus atrophic gastritis. IL-6 and HE-4 maybe of interest for the detection of antrum atrophic gastritis.
- 12 March 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (3) , 695
Open AccessSerum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study
Background: Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), a gastric precancerous lesion, is of growing interest for identification of patients at increased risk of gastric cancer. The aim was to analyze the diagnostic performance of serum pepsinogen testing using another method, chemiluminescent enzyme immunoassay (CLEIA), as well as of other new potential biomarkers. Material and Methods: The sera of patients considered at increased risk of gastric cancer and undergoing upper endoscopy collected in our previous prospective, multicenter study were tested for pepsinogen I (PGI) and II (PGII), interleukin-6 (IL-6), human epididymal protein 4 (HE-4), adiponectin, ferritin and Krebs von den Lungen (KL-6) using the CLEIA. The diagnostic performance for the detection of AG was calculated by taking histology as the reference. Results: In total, 356 patients (162 men (46%); mean age 58.6 (±14.2) years), including 152 with AG, were included. For the detection of moderate to severe corpus AG, sensitivity and specificity of the pepsinogen I/II ratio were of 75.0% (95%CI 57.8–87.9) and 92.6% (88.2–95.8), respectively. For the detection of moderate to severe antrum AG, sensitivity of IL-6 was of 72.2% (95%CI 46.5–90.3). Combination of pepsinogen I/II ratio or HE-4 showed a sensitivity of 85.2% (95%CI 72.9–93.4) for the detection of moderate to severe AG at any location. Conclusion: This study shows that PG testing by CLEIA represents an accurate assay for the detection of corpus AG. Additionally, IL-6 and HE-4 may be of interest for the detection of antrum AG. Mini- Pepsinogens testing by chemiluminescent enzyme immunoassay is accurate for the detection of corpus atrophic gastritis. IL-6 and HE-4 maybe of interest for the detection of antrum atrophic gastritis.
- Open Access
Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome
Lynch syndrome patients could benefit from various recommendations to prevent digestive cancers. In this review, we summarize the criteria to identify Lynch syndrome in patients with digestive cancers. We detail endoscopic screening procedures in patients with Lynch syndrome for gastric, small bowel, pancreatic, and colorectal cancers. We review the precise modalities of endoscopic follow-up, particularly the discrepancies that exist between the guidelines of the various scientific societies. We discuss the treatment of colorectal cancers in Lynch syndrome cases and patient adherence to endoscopic follow-up programs.
Open AccessEndoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome
Lynch syndrome patients could benefit from various recommendations to prevent digestive cancers. In this review, we summarize the criteria to identify Lynch syndrome in patients with digestive cancers. We detail endoscopic screening procedures in patients with Lynch syndrome for gastric, small bowel, pancreatic, and colorectal cancers. We review the precise modalities of endoscopic follow-up, particularly the discrepancies that exist between the guidelines of the various scientific societies. We discuss the treatment of colorectal cancers in Lynch syndrome cases and patient adherence to endoscopic follow-up programs.
- 12 May 2021
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (05) , E197-E198
Rescue lumen-apposing metal stent to treat a perforation secondary to balloon dilation of a Crohn’s disease stenosis
A 61-year-old woman was followed for ileocolic Crohnʼs disease (CD) with multi-complicated colonic and ano-perineal involvement, evolving over 17 years, with a subtotal colectomy protected by an upstream lateral ileostomy. Optimized adalimumab allowed control of the disease with healing of fistulas. However, a scarring colonic stenosis ([Fig. 1]) persisted 30 cm from the anal margin; it could not be crossed by an endoscope and prevented restoration of continuity. Hydrostatic endoscopic dilatation ([Fig. 2], [Video 1]) up to 15 mm was performed after multidisciplinary discussion. After dilation, visualization of pericolic fat confirmed digestive perforation ([Fig. 3]). The proximity between the perforation and the ileocolic anastomosis did not allow the option of a covered metallic stent. A 15-mm lumen apposing metal stent (LAMS) was used ([Fig. 4]). The colonoscope was removed and a therapeutic gastroscope was substituted because of the excessive length of the working channel of the colonoscope (140 cm). Release of the two flanges was performed under endoscopic guidance, and good positioning was confirmed by opacification without any leakage. Video 1 Rescue lumen-apposing metal stent to treat a perforation secondary to balloon dilation of a Crohn’s disease stenosis. The post-procedure care was easy, with only 5 days of oral antibiotics and return home on the first day. The LAMS was removed 1 month later with perfect healing of both the perforation and the stenosis ( [Fig.5]). The patient presents stool by the anus for the first time in 4 years, and removal of the ileostomy is being discussed. In cases of perforation during dilation of short fibrous stenosis, off-label use of LAMS through a therapeutic gastroscope seems to be a promising rescue solution. Endoscopy_UCTN_Code_CPL_1AJ_2AF Publication Date: 12 May 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 12 May 2021
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (05) , E197-E198
Rescue lumen-apposing metal stent to treat a perforation secondary to balloon dilation of a Crohn’s disease stenosis
A 61-year-old woman was followed for ileocolic Crohnʼs disease (CD) with multi-complicated colonic and ano-perineal involvement, evolving over 17 years, with a subtotal colectomy protected by an upstream lateral ileostomy. Optimized adalimumab allowed control of the disease with healing of fistulas. However, a scarring colonic stenosis ([Fig. 1]) persisted 30 cm from the anal margin; it could not be crossed by an endoscope and prevented restoration of continuity. Hydrostatic endoscopic dilatation ([Fig. 2], [Video 1]) up to 15 mm was performed after multidisciplinary discussion. After dilation, visualization of pericolic fat confirmed digestive perforation ([Fig. 3]). The proximity between the perforation and the ileocolic anastomosis did not allow the option of a covered metallic stent. A 15-mm lumen apposing metal stent (LAMS) was used ([Fig. 4]). The colonoscope was removed and a therapeutic gastroscope was substituted because of the excessive length of the working channel of the colonoscope (140 cm). Release of the two flanges was performed under endoscopic guidance, and good positioning was confirmed by opacification without any leakage. Video 1 Rescue lumen-apposing metal stent to treat a perforation secondary to balloon dilation of a Crohn’s disease stenosis. The post-procedure care was easy, with only 5 days of oral antibiotics and return home on the first day. The LAMS was removed 1 month later with perfect healing of both the perforation and the stenosis ( [Fig.5]). The patient presents stool by the anus for the first time in 4 years, and removal of the ileostomy is being discussed. In cases of perforation during dilation of short fibrous stenosis, off-label use of LAMS through a therapeutic gastroscope seems to be a promising rescue solution. Endoscopy_UCTN_Code_CPL_1AJ_2AF Publication Date: 12 May 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany